Viracta Therapeutics, Inc. (VIRX) Reports In-Line Q3 EPS

Viracta Therapeutics, Inc. (NASDAQ: VIRX) reported Q3 EPS of ($0.27), in-line with the analyst estimate of ($0.27).

For earnings history and earnings-related data on Viracta Therapeutics, Inc. (VIRX) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c
• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance